4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 53 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $4,145,000 | – | 100,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Octagon Capital Advisors LP | 377,777 | $15,659,000 | 5.43% |
BVF INC/IL | 1,106,070 | $45,847,000 | 1.80% |
Eagle Health Investments LP | 50,000 | $2,073,000 | 1.33% |
Ally Bridge Group (NY) LLC | 150,000 | $6,218,000 | 1.07% |
Casdin Capital, LLC | 780,555 | $32,354,000 | 0.96% |
VIKING GLOBAL INVESTORS LP | 3,937,914 | $163,227,000 | 0.45% |
Pinz Capital Management, LP | 19,900 | $825,000 | 0.38% |
ArrowMark Colorado Holdings LLC | 1,063,744 | $44,092,000 | 0.34% |
Perceptive Advisors | 600,256 | $24,881,000 | 0.27% |
ACUTA CAPITAL PARTNERS, LLC | 20,000 | $829,000 | 0.23% |